目的 探討炎性乳腺癌的臨床特點和治療方法。 方法 對我院1989年2月至1997年11月期間診治的17例炎性乳腺癌患者的臨床資料進行回顧性分析。 結果 17例患者中8例行新輔助化療+乳腺癌改良根治術+術后放療及化療患者的平均生存期為33.6個月，1、2、5年仍存活者分別為6例、5例和3例，行其他治療的9例患者1、2、5年仍存活者分別為5例、3例和0例。 結論 新輔助化療+乳腺癌改良根治術+術后放療及化療可提高患者生存率。
Objective To explore the effects of overexpression of human tissue inhibitors of metalloproteinase-1 (hTIMP-1) on proliferation of human liver cancer cell line HepG2 in vitro. Methods A recombinant adenoviral vector containing full-length cDNA of hTIMP-1 was generated and transfected into HepG2. The viral titer was checked by measuring GFP, and the expression of hTIMP-1 in vitro was detected by the techniques of Western blot and semi-quantitative RT-PCR. The ultrastructure was observed by transmission electron microscope and the effects of overexpression of hTIMP-1 on proliferation of HepG2 in vitro was analyzed by MTT assay and growth curve. Results The resultant AdhTIMP-1 was successfully constructed and the expression of hTIMP-1 was detected by Western blot and RT-PCR. The growth and proliferation of HepG2, which had been transfected with AdhTIMP-1, was significantly inhibited. Conclusion The proliferation of HepG2 was markedly inhibited by recombinant adenovirus-mediated overexpression of hTIMP-1, which may pave the way for further application in liver gene therapy.